Omalizumab Weight-Based Dosing Efficacy Trial — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Omalizumab Weight-Based Dosing Efficacy Trial — Stella

Recruiting

Back to Allergies trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

Trial locations(3 sites)

United States

Massachusetts General Hospital, Boston, Massachusetts

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

University of Texas Southwestern, Dallas, Texas

Key details

Phase

Safety & dosing

Sponsor

Massachusetts General Hospital

Enrollment target

~30 participants

Started

July 2025

Primary completion

May 2027

Age range

1 Year – 55 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov